At the time of writing, Transmedics Group Inc [TMDX] stock is trading at $86.98, up 5.15%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TMDX shares have gain 11.89% over the last week, with a monthly amount drifted -1.76%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, TransMedics to Present at Upcoming March Investor Conferences. In a post published today on Yahoo Finance, TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 9:50 a.m. EST and to present virtually at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 12:40 p.m. EST.
From an analyst’s perspective:
Previously, JP Morgan upgraded its rating to Overweight on August 02, 2022, and kept the price target unchanged to $48. On October 08, 2020, downgrade downgraded it’s rating to Neutral but maintained its price target of $15 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $25 on April 07, 2020. Morgan Stanley initiated its recommendation with a Equal-Weight. In a note dated May 28, 2019, Cowen initiated an Outperform rating.
For the past year, the stock price of Transmedics Group Inc fluctuated between $36.42 and $99.63. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $86.98 at the most recent close of the market. An investor can expect a potential drop of -41.37% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
According to Transmedics Group Inc [NASDAQ:TMDX], the company’s sales were 241.62M for trailing twelve months, which represents an 158.72% jump. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.19%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.22 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of4.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 82.97 points at the first support level, and at 78.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 89.16, and for the 2nd resistance point, it is at 91.33.
Transmedics Group Inc [TMDX] reported earnings per share of $0.12 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $0.15 and a surprise factor of 500.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.78 per share as compared to estimates of -$0.16 per share, a difference of -$0.62 representing a surprise of -387.50%.
Ratios To Look Out For
It is important to note that Transmedics Group Inc [NASDAQ:TMDX] has a current ratio of 9.30. Further, the Quick Ratio stands at 8.49, while the Cash Ratio is 8.7. Considering the valuation of this stock, the price to sales ratio is 11.78, the price to book ratio is 20.71.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Feb 20 when 250.0 shares were sold. Chief Commercial Officer, Khayal Tamer I completed a deal on Feb 16 to sell 2858.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 776.0 shares on Feb 15.
